PapersFlow Research Brief
Lung Cancer Treatments and Mutations
Research Guide
What is Lung Cancer Treatments and Mutations?
Lung Cancer Treatments and Mutations refers to the study of genetic alterations such as EGFR and ALK mutations in non-small-cell lung cancer (NSCLC) and the corresponding targeted therapies, including tyrosine kinase inhibitors like gefitinib and immunotherapy agents like pembrolizumab, alongside evaluation criteria for treatment response and resistance mechanisms.
Research encompasses 129,438 works on EGFR mutations, ALK inhibitors, resistance to tyrosine kinase inhibitors, clinical trials, genomic profiling, and oncogene addiction in lung cancer. Activating mutations in EGFR correlate with responsiveness to gefitinib in NSCLC patients, as shown in "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib" (Lynch et al., 2004). Revised guidelines like "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)" (Eisenhauer et al., 2008) standardize assessment of tumor response in clinical trials.
Topic Hierarchy
Research Sub-Topics
EGFR Mutations in Non-Small Cell Lung Cancer
This sub-topic characterizes exon 19 deletions, L858R, and rare EGFR mutations predicting sensitivity to tyrosine kinase inhibitors like gefitinib and osimertinib. Researchers study prevalence, ethnic differences, and co-mutations via large-scale genomic screening.
ALK Rearrangements and Inhibitors
This sub-topic examines EML4-ALK fusions and next-generation ALK inhibitors like alectinib overcoming crizotinib resistance. Researchers analyze fusion variants, brain metastases efficacy, and sequencing strategies from clinical trials.
Tyrosine Kinase Inhibitor Resistance Mechanisms
This sub-topic dissects T790M gatekeeper mutations, MET amplification, and histological transformation driving acquired resistance to EGFR/ALK TKIs. Researchers employ liquid biopsy and single-cell sequencing to map polyclonal evolution.
Genomic Profiling for Lung Cancer Therapy
This sub-topic covers comprehensive next-generation sequencing panels identifying targetable alterations beyond EGFR/ALK like ROS1, RET, and NTRK. Researchers validate tumor mutational burden and co-occurring drivers for immunotherapy selection.
PD-1/PD-L1 Inhibitors in Lung Cancer
This sub-topic evaluates pembrolizumab and nivolumab efficacy stratified by PD-L1 expression, tumor mutation burden, and combination with chemotherapy. Researchers analyze real-world outcomes and biomarkers beyond PD-L1 TPS.
Why It Matters
Targeted therapies for EGFR-mutant NSCLC, such as gefitinib, improve outcomes in patients with specific mutations; Mok et al. (2009) in "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" demonstrated gefitinib superiority over carboplatin-paclitaxel in pulmonary adenocarcinoma among East Asian nonsmokers or former light smokers, with EGFR mutations predicting better response. Immunotherapies like pembrolizumab extend progression-free and overall survival in PD-L1-positive advanced NSCLC compared to chemotherapy, per Reck et al. (2016) in "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer". Nivolumab outperforms docetaxel in advanced nonsquamous and squamous NSCLC post-platinum chemotherapy, as reported by Borghaei et al. (2015) and Brahmer et al. (2015). Recent FDA approvals, including accelerated approval for sevabertinib in non-squamous NSCLC and BLA acceptance for ivonescimab in EGFR-mutated cases, enable personalized medicine through biomarker-driven treatments.
Reading Guide
Where to Start
"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib" (Lynch et al., 2004) introduces foundational EGFR mutations and gefitinib responsiveness in NSCLC, providing essential context for targeted therapy before advancing to resistance and immunotherapies.
Key Papers Explained
"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib" (Lynch et al., 2004) and "EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy" (Paez et al., 2004) establish EGFR mutations' role in gefitinib response. "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" (Mok et al., 2009) builds on this by comparing gefitinib to chemotherapy in EGFR-mutant cases. Evaluation standards from "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)" (Eisenhauer et al., 2008) and immunotherapy trials like "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer" (Reck et al., 2016) and nivolumab studies (Borghaei et al., 2015; Brahmer et al., 2015) extend to response assessment and post-targeted therapy options.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints examine EGFR TKI resistance mechanisms and comprehensive genomic profiling at osimertinib failure, alongside mutation signatures for immunotherapy in oncogene-addicted NSCLC. News highlights FDA accelerated approval for sevabertinib in non-squamous NSCLC and BLA for ivonescimab in EGFR-mutated cases, with Bayer's Breakthrough Therapy Designation for HER2-mutant NSCLC.
Papers at a Glance
In the News
Bayer receives Breakthrough Therapy Designation in ...
## Share this page Bayer receives Breakthrough Therapy Designation in the U.S. and China for sevabertinib as a first-line treatment for patients with HER2-mutant non-small cell lung cancer Share on...
FDA Accepts BLA for Ivonescimab in Pretreated EGFR- ...
The FDA has accepted for filing a biologics license application (BLA) for ivonescimab (AK112) in combination with chemotherapy for the treatment of patients with*EGFR*-mutated, locally advanced or ...
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
This application was granted priority review. Sevabertinib received breakthrough designation and orphan drug designation. FDA expedited programs are described in the[Guidance for Industry: Expedite...
LCRF announces grant focused on curing EGFR+ lung cancers
furthering the development of novel therapies for patients with EGFRmut+ NSCLC.
FDA approves first cancer drug based on Broad Institute ...
# FDA approves first cancer drug based on Broad Institute science Collaboration between Broad Institute and Bayer leads to new treatment for a hard-to-treat type of lung cancer. By Karen Zusi-Tran ...
Code & Tools
TCR repertoire feature calculation pipeline Cancer-associated TCR enrichment scoring Machine learning models for lung cancer/malignant pulmonar...
a framework for automatic and comprehensive knowledge extraction based on mutational data from sequenced tumor samples from patients. www.intogen....
To overcome these limitations, we developed **Musta**, an _end-to-end pipeline to detect, classify_ _and interpret mutations in cancer_.
## Repository files navigation # SMURF Python implementation of SMURF (SMURF: Machine learning pipeline for discovering cancer type specific driv...
## Repository files navigation The DeepPATH framework gathers the codes that have been used to study the use of a deep learning architecture (ince...
Recent Preprints
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR -mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib
*Signal Transduction and Targeted Therapy* **volume10**, Article number:393(2025) Cite this article * 4051Accesses * 1Altmetric * Metricsdetails ### Subjects * Cancer genomics * Lung cancer ## ...
Navigating the landscape of EGFR TKI resistance in EGFR -mutant NSCLC — mechanisms and evolving treatment approaches
Resistance to EGFR tyrosine kinase inhibitors (TKIs) remains a major obstacle in the clinical management of*EGFR*-mutant non-small-cell lung cancer (NSCLC). Despite the transformative therapeutic a...
Rapidly evolving therapeutic advances for classical EGFR -mutant NSCLC
Epidermal growth factor receptor (*EGFR*) mutations represent one of the most common actionable oncogenic drivers in non–small cell lung cancer (NSCLC), affecting approximately 10-15% of patients w...
Exploring a mutation-based signature to predict the benefits of immune checkpoint inhibitors in oncogene-addicted subsets of non-small cell lung cancer: a retrospective study
Exploring a mutation-based signature to predict the benefits of immune checkpoint inhibitors in oncogene-addicted subsets of non-small cell lung cancer: a retrospective study Download PDF * Jing ...
The Clinical Characteristics, Treatment, and Prognosis of ...
Simple Summary Lung cancer in young patients (aged ≤ 45 years) is rare but increasingly recognized as a distinct disease. This study analyzed 343 young lung cancer patients treated between 2014–202...
Latest Developments
Recent developments in lung cancer treatments and mutations research as of February 2026 include FDA approvals of new therapies such as sevabertinib for non-squamous NSCLC (FDA, 2025), ongoing clinical trials like the ZG006 (Alveltamig) trial (respiratory-therapy.com, 2026), and advances in targeted therapies for actionable genomic alterations, including updates on EGFR TKI resistance mechanisms (nature.com, 2025; ascopubs.org, 2024). Additionally, novel immunotherapy combinations such as amivantamab plus lazertinib are being studied for EGFR-mutated NSCLC (nejm.org, 2024).
Sources
Frequently Asked Questions
What EGFR mutations predict response to gefitinib in NSCLC?
Somatic mutations in the EGFR gene occur in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States, correlating with clinical responsiveness to gefitinib. These mutations increase growth factor signaling and susceptibility to the inhibitor. Screening for EGFR mutations identifies responsive NSCLC subgroups, as in "EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy" (Paez et al., 2004).
How do RECIST guidelines evaluate lung cancer treatment response?
Revised RECIST guideline (version 1.1) provides criteria for assessing tumor shrinkage in solid tumors, including lung cancer, during clinical trials. It updates prior standards from the 2000 guidelines by Therasse et al. These enable consistent evaluation of cytotoxic agents and targeted therapies across international studies.
What survival benefits does pembrolizumab offer in PD-L1-positive NSCLC?
Pembrolizumab yields significantly longer progression-free and overall survival with fewer adverse events than platinum-based chemotherapy in advanced NSCLC with PD-L1 on at least 50% of tumor cells. This comes from the KEYNOTE-024 trial. Results support its use as first-line therapy in eligible patients.
Why is genomic profiling used in lung cancer treatment?
Genomic profiling identifies molecular aberrations like EGFR mutations for personalized medicine and targeted therapies. The Cancer Genome Atlas Pan-Cancer analysis reveals DNA, RNA, protein, and epigenetic differences across tumors. It informs oncogene addiction and treatment guidelines based on biomarkers.
What distinguishes nivolumab from docetaxel in advanced NSCLC?
Nivolumab extends overall survival, response rate, and progression-free survival over docetaxel in advanced nonsquamous and squamous NSCLC after platinum chemotherapy, independent of PD-L1 expression. CheckMate 057 and 017 trials confirm these benefits. It applies to previously treated patients.
Open Research Questions
- ? What mechanisms drive resistance to third-generation EGFR TKIs like osimertinib in advanced NSCLC at first-line treatment failure?
- ? How can mutation-based signatures predict immune checkpoint inhibitor benefits in oncogene-addicted NSCLC subsets?
- ? What evolving treatment approaches address EGFR TKI resistance in EGFR-mutant NSCLC?
- ? How do clinical characteristics and mutation rates in young lung cancer patients (≤45 years) influence prognosis and therapy?
- ? What novel therapies target HER2-mutant NSCLC beyond traditional EGFR and ALK inhibitors?
Recent Trends
Preprints from late 2025 focus on EGFR TKI resistance post-osimertinib, genomic profiles in treatment failure, and mutation signatures for immunotherapy benefits in oncogene-addicted NSCLC. FDA actions include accelerated approval for sevabertinib (November 2025) and BLA acceptance for ivonescimab in pretreated EGFR-mutated NSCLC (January 2026), plus Breakthrough Designation for sevabertinib in HER2-mutant NSCLC. Young lung cancer patients show 35.9% EGFR and ALK mutation rates in NSCLC.
Research Lung Cancer Treatments and Mutations with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lung Cancer Treatments and Mutations with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers